Plain-English translation of NCT06368414 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , combined with your current chronic myeloid leukemia medication, can help you achieve and maintain deeper remission. Many patients with chronic myeloid leukemia can stop taking their medications if they reach very deep remission, but some people lose that remission when they stop. This study investigates whether adding to your regular treatment might help you reach an even deeper remission level and stay off medication longer.
Some patients with chronic myeloid leukemia have tried stopping their medications but couldn't stay in remission without them. Researchers believe that by adding this medication to your current treatment, patients might achieve a deeper level of remission that lasts longer—potentially allowing them to remain off treatment for extended periods.
You likely qualify if…
You likely don't qualify if…
You would take the new medication () along with your current leukemia medication. The study team will monitor your blood work regularly to track how deeply your leukemia is responding. If you maintain very deep remission for 3 years, you would then stop both medications and be carefully monitored. If at any point your remission weakens, you would restart your regular leukemia medication—the study has a clear safety plan for this.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
South Korea
Phase
Testing effectiveness
Sponsor
Korean Society of Hematology
Enrollment target
~69 participants
Started
March 2024
Primary completion
August 2028
Age range
19 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hawk Kim
Korean Society of Hematology
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.